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Background: Mice latently infected with murine gammaherpesvirus 68 (HV-68) and transplanted with 4 T1 breast
cancer cells developed exacerbated metastatic lesions when compared to controls. The mechanisms responsible for
this viral-exacerbated disease were not clear. The ability of HV-68 infection to induce S100A8 and S100A9
production and to expand a population of CD11b+Gr-1+ cells suggested that increased numbers, or activity, of
viral-expanded myeloid derived suppressor cells (MDSCs) might contribute to HV-68-associated metastatic breast
cancer in this model. We questioned whether mock or HV-68 infected mice with significant breast cancer might
have differences in the number and/or activity of MDSCs.
Methods: Myeloid-derived macrophages and dendritic cells were isolated from normal mice and cultured in vitro
with HV-68 to assess S100A8 and S100A9 mRNA and protein expression. In vivo studies were performed using
groups of mice that were mock treated or infected with HV-68. After viral latency was established, 4 T1 breast
cancer cells were transplanted in mice. When primary breast tumors were present mice were euthanized and cells
isolated for phenotyping of myeloid cell populations using FACS, and for ex vivo analysis of suppressor activity.
Serum from these animals was also collected to quantify S100A8 and S100A9 levels.
Results: In vitro studies demonstrated that direct exposure of myeloid cells to HV-68 did not induce increased
expression of S100A8 or S100A9 mRNAs or secreted protein. HV-68 infected mice with metastatic breast cancer
disease had no increases in S100A8/A9 levels and no significant increases in the numbers or activation of CD11b
+Gr-1+MDSCs when compared to mock treated mice with breast cancer.
Conclusions: Together these studies are consistent with the notion that expanded myeloid derived suppressor
cells do not play a role in gammaherpesvirus-exacerbated breast cancer metastases. The mechanisms responsible
for HV-68 induced exacerbation of metastatic breast cancer remain unclear.
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Increased production of the damage-associated molecu-
lar pattern (DAMP) proteins, S100A8 and S100A9 [1],
has the ability to expand myeloid derived suppressor
cells (MDSCs) in vivo [2,3]. In animal models of devel-
oping cancers, increased numbers of activated MDSCs
can contribute to the immune suppression and subse-
quent metastasis of tumor cells [4,5]. Therefore exogen-
ous or endogenous stimuli which induce S100A8 and
S100A9 during developing cancers have the potential to
exacerbate such disease states by augmenting the num-
ber or activation of MDSCs [4,5].
Murine gammaherpesvirus 68 (HV-68) infection of
rodents mimics the pathophysiology of Epstein Barr
virus (EBV) [6,7], and makes this model a useful one for
investigating EBV-associated diseases. In previous stud-
ies, we found that infection with HV-68 could induce
the production of S100A8 and S100A9, and could also
expand a population of CD11b+Gr-1+MDSCs in vivo
[8]. This observation suggested that infection with HV-
68 might exacerbate cancers if this virus could augment
S100A8/A9-induced MDSCs during developing meta-
static disease. In a subsequent study, we discovered that
the presence of latent HV-68 exacerbated disease in a
transplantable breast cancer mouse model [9]. While
primary tumor growth did not vary between mock trea-
ted and HV-68 infected mice, it was clear that harboring
latent virus resulted in an exacerbation of metastatic
lesions in the lungs, as well as the growth of secondary
tumors [9]. Theoretically, HV-68 induced expansion and
activation of MDSCs could be one mechanism to explain
this viral exacerbation of metastatic breast cancer.
In our previous study, the mechanisms responsible for
HV-68 induced exacerbation of metastatic disease were
not defined [9]. Here we questioned whether virus-
expanded MDSCs might contribute to developing breast
cancer. In vitro studies were performed to investigate
whether direct exposure to HV-68 could induce myeloid
cells to express S100A8 or S100A9. We also questioned
whether HV-68 infected mice with metastatic breast can-
cer disease had increased S100A8/A9 levels or increased
numbers of activated CD11b+Gr-1+MDSCs. We found no
significant differences in virus-induced S100A8 or S100A9
or in the numbers or activation of MDSCs in infected mice
bearing breast tumors. Together these studies are consistent
with the notion that expanded myeloid derived suppressor




Six to eight week old female BALB/c mice (18–22 g)
were purchased from Jackson Laboratories (Bar Harbor,
ME) and housed in the vivarium in filter top cagescontaining sterile bedding. After arrival, mice were quar-
antined for at least five days, and fed chow and water ad
libitum. All animal experiments were in compliance with
protocols approved by the University of North Carolina
at Charlotte Animal Care and Use Committee.
Murine gammaherpesvirus-68 (HV-68)
Maintenance of viral stocks-Murine gammaherpesvirus-
68 (HV-68; ATCC # VR-1465) stocks were prepared by
infecting baby hamster kidney cells (BHK-21; ATCC #
CCL-10) at a low multiplicity of infection (MOI), fol-
lowed by preparation of cellular lysates, as described
previously [9-12].
Infection of animals-Groups of mice were anesthetized
with isoflurane and mock treated by intranasal instilla-
tion of saline, or infected intranasally with 6 × 104
plaque forming units of HV-68. Animals were housed
for 6 months following infection before transplanting 4
T1 breast cancer cells.
Assay of plaque-forming units in cell media and
lysates-Replicating HV-68 was quantified by adding 1:3
serial dilutions of cell media or lysates to BALB/3 T12-3
cell (ATCC # CCL-164) monolayers. After the mono-
layers were incubated with virus, cells were overlayed
with 1% Plaque Assay Agarose (BD Biosciences, San
Diego, CA) in medium with 30% fetal bovine serum.
After 5 days in 5% CO2, overlays were removed and cell
monolayers fixed and stained with crystal violet. All ser-
ial dilutions were performed in triplicate.
T1 breast cancer cells
Maintenance of 4 T1 cells-4 T1 cells (highly metastatic;
ATCC# CRL-2539) were used as model breast cancer cells
[13]. Cells were cultured in ATCC complete growth
medium (RPMI 1640 medium with 10% fetal bovine serum
and 2 mM L-glutamine, adjusted to contain 1.5 g/L sodium
bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM so-
dium pyruvate and 0.05 mM 2-mercaptoethanol).
Injection and monitoring of animals-To produce tumors,
3.5×104 4 T1 cells in 50 ml of phosphate-buffered saline
(PBS) were injected into the right abdominal mammary fat
pad. Following injection, animals were monitored and
weighed three times a week until the last week of the ex-
periment, when they were monitored daily.
Bone marrow-derived macrophage and dendritic
cell culture
Bone marrow derived macrophages and dendritic cells
were isolated and characterized as previously described
[10,14]. Cells were grown in ATCC complete growth
medium supplemented with M-CSF (macrophages) or
GM-CSF (dendritic cells) and incubated in 6-well plates
with HV-68 for varying lengths of time, and at various
HV-68 to cell ratios. For some cultures, LPS (1 ng/ml) was
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the indicated times, cells or culture supernatants were
taken for nucleic acid and protein analysis.
Nucleic acid analyses
Preparation of cDNA-Total RNA was isolated using
Trizol (Invitrogen; Carlsbad, CA), as previously described
[10,15-17]. RNA samples were incubated with RNase-free
pancreatic DNase (RQ1 DNase, Promega, Madison, WI)
as per the manufacturer’s instructions, the RNA precipi-
tated with EtOH and resuspended in 50 μl of nuclease-
free H2O. RNA concentrations were determined with a
Gene Spec III spectrophotometer (Naka Instruments,
Japan) using a 10 μl cuvette. For cDNA synthesis, one μg
of RNA was reverse-transcribed in the presence of ran-
dom hexamers (50 ng/μl), 10 mM dNTPs, 2.5 mM MgCl2
using ImProm-II reverse transcriptase (Promega) in the
buffer supplied by the manufacturer. cDNA was precipi-
tated with one-tenth volume of 3 M sodium acetate
(pH 5.2) and 3 volumes of EtOH, and resuspended in
50 μl of nuclease-free H2O.
Semiquantitative PCR-mRNA transcript (cDNA) levels
were examined by PCR. 100 ng of cDNA was combined
with 2.5 U of Taq polymerase (Promega), 0.2 mM each
dNTP, 25 pmol of each primer and PCR buffer contain-
ing 2.5 mM MgCl2 as provided by the manufacturer.
Samples were cycled using 95° denaturation for 35 sec-
onds, 60°C annealing for 75 seconds and 72°C extension
for 90 seconds, with the first three cycles using extended
denaturation, annealing and extension times. PCR was
for 35 cycles, except for GAPDH, which was for
28 cycles. The extension time of the last cycle was
for 5 min at 72°C. Forty percent of each amplified
PCR product was electrophoresed on an ethidium
bromide-stained 2% agarose gel and photographed under
UV illumination.
PCR primer sets were designed by using IDT SciTools
and purchased from IDT (Integrated DNA Technologies,
Coralville, IA). Primer sets used for amplification are
as follows:
ORF65 (open reading frame-65-murid herpesvirus 4;
accession no. NC_001826; 221 bp product).
Forward: 5’-ATG CTC CAG AAG AGG AAG GGA
CAC-3’.
Reverse: 5’-TTG GCA AAG ACC CAG AAG AAG
CC-3’.
GAPDH (glyceraldehyde-3-phosphate dehydrogenase;
accession no. NM_008084; 346 bp-spans exons
3 to 5).
Forward: 5’-CCA TCA CCA TCT TCC AGG AGC
GAG-3’.
Reverse: 5’-CAC AGT CTT CTG GGT GGC AGT
GAT-3’.S100A8 (calgranulin A; accession no. NM_013650;
249 bp-spans exons 2 and 3):
Forward: 5’-GAG AAG GCC TTG AGC AAC CTC
ATT G-3’.
Reverse: 5’-CCT TGT GGC TGT CTT TGT GAG
ATG-3’.
S100A9 (calgranulin B; accession no. NM_009114;
230 bp-spans exons 2 and 3):
Forward: 5’-GCA AGA AGA TGG CCA ACA AAG
CAC-3’.
Reverse: 5’-TCA AAG CTC AGC TGA TTG TCC
TGG-3’.
Protein analyses
Western blot analysis-Protein in Laemmli sample buffer
was electrophoresed on SDS-polyacrylamide gels and
transferred to Immobilon P. Filters were blocked for 2 hr
with 5% instant nonfat dried milk in TBS, incubated for
2 hr with primary antibody, washed for 30 min with TBS+
0.05% Tween 20, further incubated with HRP-conjugated
secondary antibody for 1 hr, washed and developed with
SuperSignal West Pico Chemiluminescent Substrate
(Thermo Fisher, Rockford, IL). Protein bands were visua-
lized with X-ray film. Antibodies were from R&D Systems
(Minneapolis, MN).
ELISA-S100A8/S100A9 serum levels were measured
using an Immundiagnostik S100A8/S100A9 (calprotec-
tin) ELISA kit (Alpco; Salem, NH) designed to measure
the concentration of the S100A8/S100A9 heterodimer.
Fluorescence-activated cell sorting (FACS) analysis
44 days following the injection of 4 T1 tumor cells, mice
were euthanized and tissues excised. Bone marrow cells
were isolated from the femurs of individual mice as previ-
ously described [10,15]. Splenocyte single cell suspensions
from individual mice were made by passing tissue through
a 30-gauge wire mesh. Cells were washed with sterile PBS
(300 × g for 10 min), resuspended in PBS containing 10%
non-immune rabbit serum (Invitrogen, Camarillo, CA) and
incubated on ice for 45 min with fluor-conjugated anti-
bodies (eFluor 450-anti-CD11b and PE anti-Gr-1,
eBioscience, San Diego, CA). After washing, cells were
resuspended, analyzed, and then sorted using the
FACSAria II cell sorter (BD Biosciences, San Diego, CA).
Analyses were performed on>20,000 cells per individual
spleen or bone marrow isolate.
T-cell suppression assay
Single cell suspensions of splenocytes were prepared as
described above, and red blood cells were removed using a
lysing reagent (Sigma-Aldrich, St. Louis, MO). Splenic leu-
kocytes were washed and resuspended in RPMI-1640 con-
taining 10% fetal bovine serum. CD11b+Gr-1+ cells were
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cell (MDSC) isolation kit (Miltenyi Biotec, Auburn, CA).
To isolate T lymphocytes, spleens were removed from
normal, uninfected mice, and splenic leukocytes pre-
pared as described above. Total T lymphocytes were iso-
lated using magnetic separation (Pan T cell Isolation Kit;
Miltenyi Biotec).
For co-cultures, the indicated numbers of MDSC were
added to 2 × 105 T lymphocytes in anti-CD3 coated
microtiter wells (T cell activation plates, BD Biosciences,
Bedford, MA). After 72 hours of co-incubation, the
amount of IFN-γ present in the culture supernatants
was determined using an ELISA (DuoSet mouse IFN-γ;
R&D Systems, Minneapolis, MN) as an indication of T
lymphocyte activation.Statistics
For statistical analysis, data were analyzed using GraphPad
Prism 5 software (GraphPad Software, Inc., San Diego,
CA). Analyses were performed using Student’s t-test, or by
one-way analysis of variance (ANOVA) with Tukey’s
Multiple Comparison Test as post-test. Mean values are
presented in the figures +/− the Standard Error of the
Mean (SEM). Results marked with an (*) were determined
to be statistically significant at P<0.05.Time Course
A
C
Figure 1 HV-68 virus does not induce increased S100A8 and S100A9
marrow-derived macrophages (Top panels A and B) or dendritic cells (Bott
lengths of time (Panels A and C-time course) or different multiplicities of in
with DNase to remove genomic DNA and used to synthesize cDNA. The ti
assessed by semiquantitative PCR. The viral ORF65 PCR product is presente
constitutively expressed housekeeping gene GAPDH is shown to demonstr
as amplified products electrophoresed on ethidium bromide-stained agaro
DNA standard.Results
HV-68 infection of cultured macrophages and dendritic
cells does not increase S100A8 or S100A9
mRNA expression
In previous studies, we found that infection with HV-68
could induce the production of S100A8 and S100A9, and
could also expand a population of CD11b+Gr-1+MDSCs
in vivo [8]. However it was not clear if these virus-induced
effects were direct or indirect ones. Here we questioned
whether HV-68 infection of cultured, myeloid-derived
macrophages and dendritic cells could result in the
increased expression of S100A8 and S100A9. Figure 1
shows S100A8 and S100A9 mRNA expression following
in vitro infection of macrophages and dendritic cells with
HV-68. Constitutive levels (0 hour) of S100A8 and S100A9
mRNA decreased over 48 hours in both cultured macro-
phages (Figure 1A) and dendritic cells (Figure 1C). Increas-
ing the inoculum of HV-68 on these cells had no
significant effect, or decreased, S100A8 and S100A9
mRNA expression in macrophages (Figure 1B) or dendritic
cells (Figure 1D). The ability of HV-68 to infect macro-
phages and dendritic cells was demonstrated by increases
in viral ORF65 mRNA expression (Figure 1). We con-
cluded from these studies that HV-68 infection could not
directly induce S100A8 or S100A9 mRNA expression in
these cultured myeloid cells.Dose-Response
B
D
mRNA expression in macrophages or dendritic cells in vitro. Bone
om panels C and D) were incubated with HV-68 virus for various
fection (Panels B and D-dose-response). mRNA was isolated, treated
me course of the viral induction of S100A8 and S100A9 mRNA was
d as a proxy for viral gene expression and the PCR product from the
ate similar amounts of cDNA in each sample. The results are presented
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cells does not increase the secretion of S100A8 or S100A9
protein into culture supernatants
Consistent with the mRNA data, HV-68 infection of
macrophages and dendritic cells did not result in
increased S100A8 or S100A9 protein secretion. Figure 2
shows that constitutive levels (0 hour) of S100A8 or
S100A9 protein secreted into supernatants decreased
over 48 hours in both cultured macrophages (Figure 2A)
and dendritic cells (Figure 2B). Increasing the inoculum
of HV-68 on these cells also decreased S100A8 and
S100A9 protein secreted into supernatants in macro-
phages (Figure 3A) or dendritic cells (Figure 3B). We
concluded from these studies that HV-68 infection could
not directly induce S100A8 or S100A9 protein secretion
in these cultured myeloid cells.S100A8 Control10-
15-



























Figure 2 Extracellular levels of S100A8 and S100A9 proteins do
not increase after a time course of incubation of macrophages
or dendritic cells with HV-68. Bone marrow-derived macrophages
(Panel A) or dendritic cells (Panel B) were incubated with HV-68
virus (MOI of 1:1) from zero to 48 hrs or with LPS (1 ng/ml). Medium
was mixed with 2×SDS sample buffer, boiled and proteins
electrophoresed on 15% polyacrylamide gels and protein transferred
to Immobilon P probed with anti-S100A8 and anti-S100 A9
antibodies. S100A8 and S100A9 protein levels were either
unchanged or reduced during the time course of the incubation.
Similarly, cell lysates did not show decreased levels of intracellular
S100A8 or S100A9 (data not shown).
S100A9 HV-68 
10 
Figure 3 Extracellular levels of S100A8 and S100A9 proteins do
not increase in macrophages or dendritic cells with increasing
doses of HV-68. Bone marrow-derived macrophages (Panel A) or
dendritic cells (Panel B) were incubated for 24 hrs with increasing
amounts of HV-68 virus. Medium was mixed with 2×SDS sample
buffer and protein was electrophoresed on SDS 15% polyacrylamide
gels. Protein transferred to Immobilon P was probed with
anti-S100A8 and S100A9 antibodies. S100A8 and S100A9 protein
levels in the medium were unchanged as a result of increased
amounts of HV-68 virus. Similarly, intracellular S100A8 and S100A9
levels were unchanged (data not shown).HV-68 infected mice harboring metastatic breast cancer
have no significant increases in serum S100A8/S100A9
levels or in the numbers of CD11b+Gr-1+MDSCs ex vivo
Previous studies demonstrated that HV-68 infection
alone could induce S100A8/S100A9 in vivo during acute
infection and viral latency, which was consistent with
increased MDSCs in these infected mice [8]. Previous stud-
ies also demonstrated that mice with latent HV-68 infec-
tion developed exacerbated metastatic breast cancer
disease [9]. To begin to address mechanisms that might be
responsible for this HV-68-exacerbated cancer, we ques-
tioned whether virus-induced increases in S100A8/S100A9
levels might induce increased MDSCs in vivo. Figure 4
shows that 44 days following 4 T1 tumor cell transplant-
ation, mock treated or HV-68 infected mice had no signifi-
cant differences in serum S100A8/S100A9 levels.
Consistent with these results, there were no significant
increases in CD11b+Gr-1+MDSCs when comparing mock
treated versus HV-68 infected mice. Figure 5 shows FACS
analyses from representative animals. CD11b+Gr-1+ cells
from bone marrow of mock treated (Figure 5A) versus
HV-68 infected (Figure 5B) mice showed no significant
increases in MDSCs. Similar results were observed when
analyzing splenocytes (Figure 5C versus Figure 5D).
Compiling data from groups of animals mock and

























Figure 4 ELISA quantification of S100A8 and S100A9 in sera of
mock treated or HV-68 infected mice with metastatic breast
cancer. Groups of mice were mock treated or HV-68 infected. Six
months post-infection, mice were injected with syngeneic 4 T1
mammary tumor cells into the mammary fat pad. At day 44
following tumor cell transplantation, groups of mice were
euthanized and sera isolated from individual animals. Each serum
sample was assayed for the presence of S100A8 and S100A9 using
an ELISA capable of recognizing either protein. Results are presented
as means (N = 6) ± standard errors.
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(Figure 6A), total splenocytes (Figure 6B), the percent-
age of CD11b+splenocytes (Figure 6C), or the percent-
age of CD11b+Gr-1+ bone marrow cells or splenocytes
(Figure 6D). Clearly these studies demonstrate that
HV-68 infected mice harboring metastatic breast can-
cer had no significant increases in the numbers of
CD11b+Gr-1+ MDSCs in vivo at 44 days post-breast
cancer transplantation.HV-68 infected mice harboring metastatic breast have no
significant increases in CD11b+Gr-1+MDSCs
activity in vivo
While the absolute numbers and percentages of MDSCs
were not significantly different (Figures 5 and 6), it was
possible that the suppressive activity of cells isolated from
mock versus HV-68 infected mice harboring metastatic
breast cancer might be different. To address this possibility,
CD11b+Gr-1+ cells were isolated from individual mice and
assayed for their ability to suppress anti-CD3-induced T
cell activation [4]. Figure 7 shows that MDSCs isolated
from either group could effectively suppress T cell induced
interferon gamma secretion in co-cultures. However no
significant differences in the ability to suppress T cell acti-
vation could be seen when comparing equal numbers of
MDSCs isolated from mock treated (Figure 7, white bars)
versus HV-68 infected (Figure 7, black bars) mice harbor-
ing metastatic breast cancer.Discussion
The relationship between EBV infection and breast cancer
has been the subject of numerous investigations [18-22].
Some studies have demonstrated the presence of EBV
genes or proteins in breast cancer biopsies [20,23-27],
while other studies have suggested a relationship between
aggressive breast cancers and the presence of EBV [28]. In
contrast, other studies have not detected significant differ-
ences in viral gene or protein expression in breast cancer
tissues [29-34]. Therefore the association of EBV with
breast cancer remains controversial, and more definitive
studies in patients are limited by ethical constraints.
In a recent study, we investigated the possibility that the
presence of a latent gammaherpesvirus might exacerbate
disease in a transplantable breast cancer using mouse mod-
els [9]. HV-68 is a murine gammaherpesvirus which
mimics the pathophysiology of EBV [6,7]. Upon intranasal
or oral inoculation in mice [12], there is a productive infec-
tion of epithelial cells, followed by infection of B lympho-
cytes, and also macrophages and dendritic cells. A marked
leukocytosis (i.e. mononucleosis) and splenomegaly occurs,
which peaks around 15 days post-infection and results in
the establishment of latency for the life of the host. The
ability of HV-68 to establish latency in mice makes
this model a useful one for investigating EBV-associated
diseases.
The transplantable 4 T1 mammary tumor [13] forms pri-
mary tumors at the site of injection into the mammary fat
pad. Metastatic lesions begin to appear in tissues, including
the lung and liver, several weeks after transplanting cells.
Combining HV-68 latency, with mice developing 4 T1
mammary tumors, allowed a direct analysis of whether this
gammaherpesvirus could infect breast carcinoma cells
in vivo, and whether disease was exacerbated when com-
pared to uninfected animals. Mice harboring latent HV-68
had dramatic increases in metastatic disease [9]. This exa-
cerbated metastasis was not due to direct HV-68 infection
of 4 T1 cells or to detectable levels of virus within the
tumor masses. Therefore, the most likely explanation for
HV-68 exacerbated metastatic breast cancer disease in this
model was an indirect one. Unfortunately, the nature of
this indirect effect was not clear from our previous studies,
and could include factors expressed by virally infected
leukocytes, or viral-induced alterations in the host’s
immune response.
In the present study, we began to address possible
mechanisms that might explain HV-68-exacerbated
breast cancer metastasis. The rationale for the present
work stems from our discovery that infection with this
gammaherpesvirus resulted in an increase in S100A8/A9
production in vivo, which correlated with an increase in
CD11b+Gr-1+ cells [8]. This finding was significant
since this is the phenotype of MDSCs [4], and since









A       Bone Marrow-Mock B    Bone Marrow-HV-68
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Figure 5 Percentage of splenic CD11b+Gr-1+cells in mock treated and HV-68 infected mice with metastatic breast cancer. Groups of
mice were mock treated or HV-68 infected. Six months post-infection, mice were injected with syngeneic 4 T1 mammary tumor cells in the
mammary fat pad. At day 44 following tumor cell transplantation, groups of mice were euthanized and tissues were isolated. Bone marrow cells
and splenocytes were isolated and labeled with fluorchrome-conjugated anti-CD11b and anti-Gr-1 antibodies. FACS analysis of one representative
animal per group shows the percentage of CD11b+Gr-1+cells (upper right quadrant) from the bone marrow (Panel A) or spleen (Panel C) of a
mock-treated mouse, or from the bone marrow (Panel B) or spleen (Panel D) of an HV-68 infected mouse that have 4 T1 breast
cancer metastases.
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proteins that form noncovalent homodimers and a het-
erodimer (S100A8/A9) in a calcium-dependent manner
[1]. These proteins have been shown to be critically im-
portant for the accumulation of MDSCs in cancer mod-
els [2,3]. MDSCs are hematopoietic precursors of
macrophages, granulocytes, and dendritic cells [4]. These
immature cells are CD11b+Gr-1+ and this population of
cells can be dramatically expanded during some develop-
ing cancers [5]. These cells have been implicated in lim-
iting the immune response, with a particular focus on
their ability to suppress T lymphocyte activation [4]. Fol-
lowing HV-68 infection, we found that serum levels ofS100A8 or S100A9 increase during acute infection and
are maintained during the establishment of viral latency
[8]. The importance of these proteins for expanding
MDSCs suggested one likely mechanism to account for
the accumulation of HV-68 induced CD11b+Gr1+ cells
in the spleen [8].
Theoretically, if HV-68 infected mice were able to
expand MDSCs during developing mammary tumor
metastases, this might be one mechanism to explain
viral-exacerbated disease. In vitro studies demonstrated
that direct exposure of myeloid cells to HV-68 did
not induce increased expression of S100A8 or S100A9



































































































Figure 6 The number and percentage of CD11b+ and CD11b+Gr-1+cells in mock treated and HV-68 infected mice with metastatic
breast cancer were not significantly different. Groups of mice were mock treated or HV-68 infected. Six months later mice were injected with
syngeneic 4 T1 mammary tumor cells in the mammary fat pad. At day 44 following tumor cell transplantation, groups of mice were euthanized
and tissues were isolated. Splenomegaly (Panel A) and the total number of leukocytes per spleen (Panel B) were determined. Bone marrow cells
and splenic leukocytes were isolated from individual animals and labeled with fluorchrome-conjugated anti-CD11b and anti-Gr-1 antibodies. The
percentage of CD11b+splenic leukocytes (Panel C) or CD11b+Gr-1+bone marrow cells or splenic leukocytes (Panel D) were determined by FACS
analyses. Results are presented as mean values (N = 8) ± standard errors. These studies were performed twice with similar results.
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ing infection. This result suggested that increased serum
levels of S100A8 or S100A9 during acute infection and
early latency [8] are not due to a direct effect of viral in-
fection on macrophages or dendritic cells. Furthermore,
HV-68 infected mice with metastatic breast cancer dis-
ease had no increases in serum levels of S100A8/A9
when compared to mock treated controls at 44 days
post 4 T1 transplantation (Figure 4). Similarly, there
were no significant differences in the percentages of
CD11b+Gr-1+ cells in the spleens or bone marrow of
HV-68 infected mice with a substantial tumor burden
when compared to mock treated controls. Similar levels
of splenomegaly, (Figure 6A), numbers of total spleno-
cytes (Figure 6B), and percentages of total CD11b+ cells
(Figure 6C) demonstrated that the absolute number
of CD11b+Gr-1+ cells did not differ. It should be
noted that the results shown here represent serum levels
of S100A8/A9 and numbers of CD11b+Gr-1+ cells
at an experimental endpoint (i.e. 44 days post 4 T1
transplantation and 226 days post-HV-68 infection).Future studies are aimed at determining if S100A8/A9
levels and CD11b+Gr-1+ numbers remained unchanged
or were variable throughout the course of breast
tumor development.
While the numbers of MDSCs were similar in HV-68
and mock treated mice with 4 T1 breast cancer, we also
questioned whether there might be a difference in their
suppressive activity. MDSCs can limit the immune re-
sponse using a variety of mechanisms, and can suppress
T lymphocyte function [4]. Mechanisms of MDSC sup-
pressive activity include the production of arginase,
iNOS, and reactive oxygen or nitrogen species by these
cells, as well as their ability to induce T regulatory cells.
Therefore we compared the suppressive activity of
MDSCs isolated from HV-68 infected or mock treated
mice bearing tumors using a standard co-culture sup-
pression assay that stimulated T cells with anti-CD3 to
induce interferon gamma production. While the MDSCs
from both groups of animals demonstrated the ability to
suppress T cell cytokine production in a dose-dependent









































Figure 7 CD11b+Gr-1+cells in mock treated and HV-68 infected
mice with metastatic breast cancer suppressed
anti-CD3-induced T cell activation. Groups of mice were mock
treated (white bars) or HV-68 infected (black bars). Six months
post-infection, mice were injected with syngeneic 4 T1 mammary
tumor cells in the mammary fat pad. At day 44 following tumor
cell transplantation, groups of mice were euthanized and
CD11b+Gr-1+cells were isolated from spleens of individual mice.
The indicated numbers of CD11b+Gr-1+cells were added to 2 × 105
cultured T lymphocytes stimulated with anti-CD3 antibodies. After
72 hours of co-incubation, culture supernatants were assayed for
interferon gamma (IFN-γ) production as a measure of T cell
activation. Results are presented as means (N= 4) ± standard errors
with asterisks indicating a statistically significant difference (p < 0.05)
as numbers of CD11b+Gr-1+cells become limiting.
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http://www.infectagentscancer.com/content/7/1/22suppressive activity of the MDSCs on a per cell basis re-
gardless of the group of animals that these cells were
isolated from (Figure 7).
Taken together these studies are consistent with the
notion that expanded myeloid derived suppressor cells
are not responsible for gammaherpesvirus-exacerbated
breast cancer metastases. At 44 days following trans-
plantation of 4 T1 cells, animals had a substantial pri-
mary and metastatic tumor burden [9]. Mice that
harbored latent HV-68 had greatly exacerbated meta-
static disease [9]. The present study does not support
the notion that MDSCs contributed to exacerbated
breast cancer metastases when analyzed at a time when
mice had a substantial tumor burden (e.g. 44 days fol-
lowing transplantation). Whether there are differences in
the number, or activity, of MDSCs earlier in developing
breast cancer disease in HV-68 versus mock treated
mice will be the subject of future investigations. Since
HV-68 does not directly infect 4 T1 breast cancer cellsin this model [9], the indirect mechanisms responsible
for viral-induced exacerbation of metastatic breast
cancer remain unclear. However the present study
demonstrates the value of using HV-68 as a model to
dissect possible mechanisms responsible for exacerbated
disease, as such studies would not be possible using
human subjects.
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